{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:57:26Z","timestamp":1785495446724,"version":"3.56.0"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Osteosarcoma is an aggressive malignancy characterized by inherent chemoresistance, a high propensity for pulmonary metastasis, and dismal survival rates in patients with advanced or refractory disease. While immunotherapy has revolutionized cancer treatment, its efficacy in osteosarcoma remains severely limited by an immunologically \u201ccold\u201d and profoundly immunosuppressive tumor microenvironment (TME). This TME is defined by pervasive infiltrates of tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs), cancer-associated fibroblasts (CAFs), and a dense mineralized extracellular matrix (ECM) barrier that collectively exclude or exhaust cytotoxic T cells. We examine the intricate mechanisms driving this immunotherapy resistance at the cellular and molecular levels. We then explore how rationally designed nanotechnology platforms can overcome these barriers. Specifically, we review targeted nanomedicine delivery systems engineered to home to bone tissue and reshape the TME landscape via strategies including TAM reprogramming, MDSC depletion, ECM clearance to relieve physical resistance, and activation of innate immune pathways. Unlike general immunotherapy reviews, the main contribution of this mini-review is strictly focused on innovative nanomedicine delivery platforms\u2014specifically biomimetic, stimuli-responsive, and bone-targeted systems. We dissect how these rationally engineered platforms overcome the unique physical and cellular barriers of the osteosarcoma TME, with a critical emphasis on the severe translational hurdles, such as protein corona formation and\n                    <jats:italic>in vivo<\/jats:italic>\n                    stability, that limit clinical progression. In conclusion, multi-targeted nanomedicine delivery systems hold strong preclinical potential to provide a novel framework for advancing osteosarcoma treatment by precisely modulating the TME and eliciting durable antitumor immune responses.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1897106","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:58:30Z","timestamp":1785491910000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Engineering immunity in osteosarcoma: nanomedicine strategies for overcoming immune evasion"],"prefix":"10.3389","volume":"17","author":[{"given":"Qin","family":"Huang","sequence":"first","affiliation":[{"name":"Neck-Shoulder and Lumbocrural Pain Hospital of Shandong First Medical University, Shandong First Medical University & Shandong Academy of Medical Sciences","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gongchang","family":"Yu","sequence":"additional","affiliation":[{"name":"Neck-Shoulder and Lumbocrural Pain Hospital of Shandong First Medical University, Shandong First Medical University & Shandong Academy of Medical Sciences","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Shi","sequence":"additional","affiliation":[{"name":"Neck-Shoulder and Lumbocrural Pain Hospital of Shandong First Medical University, Shandong First Medical University & Shandong Academy of Medical Sciences","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Deng","sequence":"additional","affiliation":[{"name":"College of Health and Elderly Care, Shandong Women\u2019s University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/ph18040520","article-title":"Advancements in osteosarcoma therapy: Overcoming chemotherapy resistance and exploring novel pharmacological strategies","volume":"18","author":"Zhra","year":"2025","journal-title":"Pharm Basel"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2022.18","article-title":"An overview of resistance to chemotherapy in osteosarcoma and future perspectives","volume":"5","author":"Garcia-Ortega","year":"2022","journal-title":"Cancer Drug Resist"},{"key":"B3","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12943-025-02365-z","article-title":"Targeting metastasis in paediatric bone sarcomas","volume":"24","author":"Bull","year":"2025","journal-title":"Mol Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1007\/s12672-025-02208-9","article-title":"Systemic strategies for osteosarcoma: Advances and future directions","volume":"16","author":"Morya","year":"2025","journal-title":"Discov Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010272","article-title":"Current state of immunotherapy and mechanisms of immune evasion in Ewing sarcoma and osteosarcoma","volume":"15","author":"Evdokimova","year":"2022","journal-title":"Cancers Basel"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1702219","article-title":"Decoding the immune microenvironment in osteosarcoma: New insights into checkpoints, vaccines, and CAR-T cells","volume":"15","author":"Wang","year":"2025","journal-title":"Front Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41413-023-00246-z","article-title":"Managing the immune microenvironment of osteosarcoma: The outlook for osteosarcoma treatment","volume":"11","author":"Tian","year":"2023","journal-title":"Bone Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/cells13030233","article-title":"IL-1 family members in bone sarcomas","volume":"13","author":"Landuzzi","year":"2024","journal-title":"Cells"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2025.101569","article-title":"Tumor microenvironment in osteosarcoma: From cellular mechanism to clinical therapy","volume":"12","author":"Yu","year":"2025","journal-title":"Genes Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1668535","article-title":"Cancer-associated fibroblasts in osteosarcoma: Key players in immune escape and targeted therapy","volume":"16","author":"Fan","year":"2025","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.4c12532","article-title":"Photothermal-triggered extracellular matrix clearance and dendritic cell maturation for enhanced osteosarcoma immunotherapy","volume":"16","author":"Yu","year":"2024","journal-title":"ACS Appl Mater Interfaces"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1621521","article-title":"The Malignant dialogue between cancer-associated fibroblasts and osteosarcoma cells: Microenvironment-mediated drug resistance and therapeutic targets","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioadv.2023.213466","article-title":"Multifunctional nanoparticles for the treatment and diagnosis of osteosarcoma","volume":"151","author":"Yuan","year":"2023","journal-title":"Biomater Adv"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1269224","article-title":"Engineered nanomaterials enhance drug delivery strategies for the treatment of osteosarcoma","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15122717","article-title":"Nano-based drug delivery systems: Potential developments in the therapy of metastatic osteosarcoma-a narrative review","volume":"15","author":"Luo","year":"2023","journal-title":"Pharmaceutics"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.s549587","article-title":"Nanotechnology-driven strategies in osteosarcoma advances in treatment: Immunotherapy and drug delivery","volume":"20","author":"Su","year":"2025","journal-title":"Int J Nanomedicine"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/jfb16060213","article-title":"Material-driven therapeutics: Functional nanomaterial design paradigms revolutionizing osteosarcoma treatment","volume":"16","author":"Zhang","year":"2025","journal-title":"J Funct Biomater"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.s579152","article-title":"Nanoparticles targeting the tumor microenvironment for the treatment of osteosarcoma: Recent progress and perspectives","volume":"21","author":"Liang","year":"2026","journal-title":"Int J Nanomedicine"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.909408","article-title":"Bone-targeted nanoparticle drug delivery system: An emerging strategy for bone-related disease","volume":"13","author":"Chen","year":"2022","journal-title":"Front Pharmacol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.03.001","article-title":"Engineering small-molecule and protein drugs for targeting bone tumors","volume":"32","author":"Wang","year":"2024","journal-title":"Mol Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioactmat.2026.03.032","article-title":"Manganese-potentiated cGAS-STING activation with ATM\/PRMT5 inhibition remodels the immunosuppressive microenvironment in osteosarcoma via bone-targeted delivery","volume":"63","author":"Tong","year":"2026","journal-title":"Bioact Mater"},{"key":"B22","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s10555-025-10257-3","article-title":"Microenvironment matters: Insights from the FOSTER consortium on microenvironment-driven approaches to osteosarcoma therapy","volume":"44","author":"Dutour","year":"2025","journal-title":"Cancer Metastasis Rev"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1802194","article-title":"Immune exclusion as a recurrent immune-escape state driving treatment resistance in osteosarcoma: Insights from single-cell, spatial, and multi-omics studies","volume":"17","author":"Zeng","year":"2026","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41413-022-00237-6","article-title":"Characterizing the tumor microenvironment at the single-cell level reveals a novel immune evasion mechanism in osteosarcoma","volume":"11","author":"Liu","year":"2023","journal-title":"Bone Res"},{"key":"B25","article-title":"The role of macrophages in sarcoma tumor microenvironment and treatment","volume":"15","author":"Zaj\u0105c","year":"2023","journal-title":"Cancers Basel"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-021-00598-w","article-title":"The role of tumor-associated macrophages in osteosarcoma progression - therapeutic implications","volume":"44","author":"Huang","year":"2021","journal-title":"Cell Oncol Dordr"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.114592","article-title":"Multifunctional poly(amino acid) nanomedicine modulates macrophage polarization for osteosarcoma immunotherapy","volume":"391","author":"Sun","year":"2026","journal-title":"J Control Release"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1548527","article-title":"Progress in immune microenvironment, immunotherapy and prognostic biomarkers in pediatric osteosarcoma","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202409870","article-title":"Osteosarcoma cell-derived migrasomes promote macrophage M2 polarization to aggravate osteosarcoma proliferation and metastasis","volume":"12","author":"Liu","year":"2025","journal-title":"Adv Sci Weinh"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1658358","article-title":"Role of tumor-derived exosomes and immune cells in osteosarcoma progression and targeted therapy","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13046-022-02372-8","article-title":"Nanoengineering a metal-organic framework for osteosarcoma chemo-immunotherapy by modulating indoleamine-2,3-dioxygenase and myeloid-derived suppressor cells","volume":"41","author":"Fan","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1271321","article-title":"Potential targets and applications of nanodrug targeting myeloid cells in osteosarcoma for the enhancement of immunotherapy","volume":"14","author":"Zhu","year":"2023","journal-title":"Front Pharmacol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2147\/itt.s485672","article-title":"Myeloid cells in the immunosuppressive microenvironment as immunotargets in osteosarcoma","volume":"14","author":"Sholevar","year":"2025","journal-title":"Immunotargets Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2025.114612","article-title":"Decoding the function of cancer-associated fibroblasts in osteosarcoma: Molecular pathways, therapeutic approaches and prognostic significance","volume":"450","author":"Hsu","year":"2025","journal-title":"Exp Cell Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12943-025-02516-2","article-title":"Targeting OxLDL-mediated CD36\u2009+\u2009CAF reprogramming potentiates PD-1 immunotherapy in osteosarcoma","volume":"25","author":"Zeng","year":"2025","journal-title":"Mol Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1728091","article-title":"Epigenetic control of antigen presentation failure in osteosarcoma: From single-cell chromatin maps to therapeutic strategies","volume":"16","author":"He","year":"2025","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15237","article-title":"Thrombospondin-1 induced programmed death-ligand 1-mediated immunosuppression by activating the STAT3 pathway in osteosarcoma","volume":"113","author":"Liu","year":"2022","journal-title":"Cancer Sci"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.s285560","article-title":"The updated status and future direction of immunotherapy targeting B7-H1\/PD-1 in osteosarcoma","volume":"13","author":"Fan","year":"2021","journal-title":"Cancer Manag Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24010799","article-title":"Strategies to overcome resistance to immune-based therapies in osteosarcoma","volume":"24","author":"Hattinger","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2010.03.005","article-title":"Engineered macrophage nanoparticles enhance microwave ablation efficacy in osteosarcoma via targeting the CD47-SIRP\u03b1 axis: A novel biomimetic immunotherapeutic approach","volume":"47","author":"Ji","year":"2025","journal-title":"Bioact Mater"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13122878","article-title":"Drug resistance in osteosarcoma: Emerging biomarkers, therapeutic targets and treatment strategies","volume":"13","author":"Hattinger","year":"2021","journal-title":"Cancers Basel"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1217669","article-title":"Metabolism and senescence in the immune microenvironment of osteosarcoma: Focus on new therapeutic strategies","volume":"14","author":"Ying","year":"2023","journal-title":"Front Endocrinol Lausanne"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2022.12.016","article-title":"Translational nanomedicine potentiates immunotherapy in sarcoma by normalizing the microenvironment","volume":"353","author":"Mpekris","year":"2023","journal-title":"J Control Release"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121407","article-title":"Enhancement of anti-PD-1\/PD-L1 immunotherapy for osteosarcoma using an intelligent autophagy-controlling metal organic framework","volume":"282","author":"Ge","year":"2022","journal-title":"Biomaterials"},{"key":"B45","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.bioactmat.2025.01.006","article-title":"TME-responsive nanocomposite hydrogel with targeted capacity for enhanced synergistic chemoimmunotherapy of MYC-amplified osteosarcoma","volume":"47","author":"Ma","year":"2025","journal-title":"Bioact Mater"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2025.102095","article-title":"Reshaping tumor immune microenvironment and modulating T cell function based on hierarchical nanotherapeutics for synergistically inhibiting osteosarcoma","volume":"34","author":"Li","year":"2025","journal-title":"Mater Today Bio"},{"key":"B47","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1038\/s41467-019-12384-2","article-title":"Modulation of M2 macrophage polarization by the crosstalk between Stat6 and Trim24","volume":"10","author":"Tao","year":"2019","journal-title":"Nat Commun"},{"key":"B48","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3390\/cancers6020897","article-title":"STAT3 target genes relevant to human cancers","volume":"6","author":"Richard","year":"2014","journal-title":"Cancers"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.10.7303","article-title":"Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: New molecules and patterns of gene expression","volume":"177","author":"Fernando","year":"2006","journal-title":"J Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.freeradbiomed.2019.12.018","article-title":"Scavenging reactive oxygen species selectively inhibits M2 macrophage polarization and their pro-tumorigenic function in part, via Stat3 suppression","volume":"147","author":"Brandon","year":"2019","journal-title":"Free Radic Biol Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1159\/000479439","article-title":"Lanthanum chloride inhibits LPS mediated expressions of pro-inflammatory cytokines and adhesion molecules in HUVECs: Involvement of NF-\u03baB-Jmjd3 signaling","volume":"42","author":"Xia","year":"2017","journal-title":"Cell Physiol Biochem"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20090560","article-title":"Aryl hydrocarbon receptor in combination with Stat1 regulates LPS-induced inflammatory responses","volume":"206","author":"Akihiro","year":"2009","journal-title":"J Exp Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202400538","article-title":"Enhanced osteosarcoma immunotherapy via CaCO(3) nanoparticles: Remodeling tumor acidic and immune microenvironment for photodynamic therapy","volume":"13","author":"Gao","year":"2024","journal-title":"Adv Heal Mater"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2025.101607","article-title":"Bioinspired nanomedicines for the management of osteosarcoma: Recent progress and perspectives","volume":"32","author":"Cui","year":"2025","journal-title":"Mater Today Bio"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202309038","article-title":"ZIF-8-encapsulated pexidartinib delivery via targeted peptide-modified M1 macrophages attenuates MDSC-mediated immunosuppression in osteosarcoma","volume":"20","author":"Dong","year":"2024","journal-title":"Small"},{"key":"B56","doi-asserted-by":"crossref","first-page":"1403538","DOI":"10.3389\/fimmu.2024.1403538","article-title":"Make it STING: Nanotechnological approaches for activating cGAS\/STING as an immunomodulatory node in osteosarcoma","volume":"15","author":"O\u2019Donoghue","year":"2024","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.5c08888","article-title":"Copper-induced cuproptosis and immunogenic cell death synergize with radiotherapy and PD-1 blockade in osteosarcoma","volume":"17","author":"Yao","year":"2025","journal-title":"ACS Appl Mater Interfaces"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202410427","article-title":"Biomimetic targeted co-delivery system engineered from genomic insights for precision treatment of osteosarcoma","volume":"12","author":"Luo","year":"2025","journal-title":"Adv Sci Weinh"},{"key":"B59","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s12032-025-02853-8","article-title":"Barriers in bone tumor treatment: The emerging role of drug delivery systems","volume":"42","author":"Liu","year":"2025","journal-title":"Med Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2022.08.048","article-title":"IL-11R\u03b1-targeted nanostrategy empowers chemotherapy of relapsed and patient-derived osteosarcoma","volume":"350","author":"Jiang","year":"2022","journal-title":"J Control Release"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-23-0772","article-title":"Tumor microenvironment reprogramming improves nanomedicine-based chemo-immunotherapy in sarcomas","volume":"23","author":"Charalambous","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"B62","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1186\/s40001-023-01309-x","article-title":"Competitive endogenous network of circRNA, lncRNA, and miRNA in osteosarcoma chemoresistance","volume":"28","author":"Qin","year":"2023","journal-title":"Eur J Med Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.22167","article-title":"Deciphering chemoresistance in osteosarcoma: Unveiling regulatory mechanisms and function through the lens of noncoding RNA","volume":"85","author":"Chen","year":"2024","journal-title":"Drug Dev Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.s471900","article-title":"Delivery of miRNAs using nanoparticles for the treatment of osteosarcoma","volume":"19","author":"Wang","year":"2024","journal-title":"Int J Nanomedicine"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1133726","article-title":"Exosomes and osteosarcoma drug resistance","volume":"13","author":"Fu","year":"2023","journal-title":"Front Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.737314","article-title":"Exosomes as efficient nanocarriers in osteosarcoma: Biological functions and potential clinical applications","volume":"9","author":"Yang","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s10637-025-01551-6","article-title":"The therapeutic potential of exosomes in bone cancers: Osteosarcoma, chondrosarcoma, and Ewing sarcoma","volume":"43","author":"Jamil","year":"2025","journal-title":"Invest New Drugs"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.s539722","article-title":"In vivo testing of nanotherapeutics for osteosarcoma treatment: Translational challenges and solutions","volume":"20","author":"D\u2019Anna","year":"2025","journal-title":"Int J Nanomedicine"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1039\/d4ra01026d","article-title":"Cancer cell membrane-coated nanoparticles: A promising anti-tumor bionic platform","volume":"14","author":"Qiuyan","year":"2024","journal-title":"RSC Adv"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.s273713","article-title":"Distinct proteins in protein corona of nanoparticles represent a promising venue for endogenous targeting \u2013 Part I: In vitro release and intracellular uptake perspective","volume":"15","author":"Aya","year":"2020","journal-title":"Int J Nanomedicine"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1897106\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:58:31Z","timestamp":1785491911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1897106\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":70,"alternative-id":["10.3389\/fimmu.2026.1897106"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1897106","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"article-number":"1897106"}}